The Chinese drug administration approved the supplementary application of Guangzhou Baiyunshan Pharmaceutical's (SHA:600332, HKG:0874) unit, Baiyunshan Pharmaceutical General Factory, to make changes to selaginella jiangnanensis tablets' instructions, according to a Shanghai Stock Exchange filing on Wednesday.
The changes included safety instructions for the drug's usage and other details, the pharmaceutical company said.
The drug is used for subcutaneous purpura caused by blood heat.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments